Drug Profile
Research programme: orally administered colon specific therapeutics - Samyang
Alternative Names: SY-CSDS therapeutics - SamyangLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation; Samyang Group
- Developer Samyang Biopharmaceuticals Corporation
- Class Aminosalicylic acids; Corticosteroids; Glucocorticoids; Phenethylamines; Pregnadienetriols; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants; Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in South Korea (PO, Controlled release)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in South Korea (PO, Controlled release)